The epidermal growth factor receptor (EGFR) is linked to poor outcome in breast cancer, and resistance to hormonal therapy is often accompanied by activation of growth factor receptors. To investigate the mechanism(s) by which EGFR becomes activated in breast cancer, we screened a cDNA expression library for genes that mediate EGF-independent proliferation of human mammary epithelial cells (HMECs). We isolated the NSEP1 cDNA encoding Y-box-binding protein 1 (YB-1), a multifunctional transcriptional and translational regulator. This cDNA conferred growth factor independence to HMECs. YB-1-transduced cells overexpressed EGFR, but ErbB-2 (Her-2/neu) levels were unchanged. Moreover, EGFR was constitutively phosphorylated in the absence of exogenous ligand. In these cells, an EGFR-blocking antibody failed to inhibit proliferation, conditioned medium activity could not be detected, and the synthesis of EGFR ligands was reduced compared to parental cells. This suggests that EGFR is activated in a ligandindependent fashion. However, cell growth could be blocked with an ErbB kinase inhibitor, indicating that EGFR signaling plays a major role in YB-1-induced growth factor independence. Taken together, our results demonstrate that YB-1 overexpression can induce EGF independence in HMECs via activation of the EGFR pathway. This could represent one of the mechanisms by which YB-1 contributes to breast tumor aggressiveness.
Introduction
Expression of the epidermal growth factor receptor (EGFR) occurs in a subset of breast tumors and is an indicator of early relapse and poor prognosis (Klijn et al., 1992; Fox and Harris, 1997; Salomon et al., 2000; Nicholson et al., 2001) . Moreover, breast cancer cells that are hormone-independent or have acquired resistance to hormonal therapy frequently express EGFR (Gee et al., 2003) . Since EGFR is a strong prognostic indicator for poor survival independent of estrogen receptor status, EGFR activation may be an important step in the progression to estrogen independence. However, the mechanism of EGFR overexpression is unclear, as gene amplifications at this locus are uncommon in breast cancer (Kersting et al., 2004) . We hypothesized that genetic alterations in tumor cells that result in EGFR overexpression or activation may confer EGF-independent growth to HMECs. To identify candidate genes expressed by breast cancer cells that mediate growth factor autonomy, we utilized an expression cloning strategy. A cDNA encoding the EGF family member amphiregulin was previously isolated using this strategy (Berquin et al., 2001) . Here, we describe the isolation of another cDNA, encoding the transcriptional and translational regulator, Y-boxbinding protein 1 (YB-1).
YB-1 is a multifunctional protein belonging to the cold-shock domain family, also known as nucleasesensitive element-binding protein 1 (NSEP1; Kolluri and Kinniburgh, 1991; Kolluri et al., 1992) or DNA-binding protein B (dbpb; Sakura et al., 1988) . Abnormal YB-1 staining has been found in several cancer types, including breast cancer (Bargou et al., 1997) , osteosarcoma (Oda et al., 1998) , ovarian adenosarcoma (Kamura et al., 1999) , colorectal carcinoma (Shibao et al., 1999) , lung cancer (Gu et al., 2001) , and prostate cancer (Gimenez-Bonafe et al., 2004) . Nuclear localization of YB-1 in breast tumor samples correlated with expression of the multidrug resistance gene MDR1 (Bargou et al., 1997) and YB-1 was found to be directly involved in MDR1 gene activation in response to genotoxic stress . YB-1 was also shown to be overexpressed in breast cancer during a screen for breast cancer-associated proteins using combinatorial immunoglobulin phage libraries (Rubinstein et al., 2002) . Another report showed that YB-1 mRNA levels were elevated in a subset of breast cancer samples and cell lines with other markers characteristic of aggressive lesions (Sorlie et al., 2001) . High expression or nuclear staining for YB-1 in breast tumors predicted bad outcome (Janz et al., 2002) . The present study investigates the role of YB-1 in EGF independence and EGFR activation in HMECs.
Results

Isolation of a cDNA encoding YB-1
To investigate the mechanism(s) by which EGFR is expressed and activated in breast cancer, we screened a cDNA expression library for genes that mediate EGFindependent proliferation of HMECs. The construction of a retroviral cDNA library from SUM-149PT breast cancer cells was described previously (Berquin et al., 2001) . The SUM-149PT cell line was derived from a premenopausal patient with aggressive, inflammatory breast cancer. We found that these cells are EGFindependent in culture, overexpress EGFR, and are sensitive to an ErbB kinase inhibitor (Rao et al., 2000) . We transduced the SUM-149PT cDNA library into HPV-16-immortalized H16N2 HMECs, and selected recipient cells at low density in serum-free medium lacking EGF and insulin (SFH medium) for 8 weeks. H16N2 cells infected with control virus failed to form colonies under these conditions. However, libraryinfected H16N2 cells yielded three clones in one experiment. One of these clones contained the amphiregulin cDNA (Berquin et al., 2001) . A second clone (H56b#2) contained two different cDNAs that were amplified by RT-PCR using vector-specific primers ( Figure 1a , lane 2). The size of the largest PCR product was 2 kb, including 0.5 kb of vector sequence and a 1.5 kb cDNA encoding YB-1 (gene symbol NSEP1, Genbank Accession number NM_004559). The other PCR product was 1.2 kb in length and contained a 0.7-kb fragment of the mitochondrial enoyl coenzyme A hydratase short chain 1 cDNA. Both cDNAs contained a poly(A) tail at their 3 0 end, but only YB-1 contained a full coding region.
The YB-1 cDNA is sufficient to confer EGF independence to HMECs
The two cDNAs recovered from the EGF-independent cell clone were transduced individually into H16N2 cells to determine if they could transfer the ability to grow in the absence of growth factors. The YB-1 cDNA was able to confer EGF independence in this assay (Figure 1b ), whereas the enoyl coenzyme A hydratase cDNA was not (data not shown). Both clonal and polyclonal populations were propagated from the H16N2 cells transduced with YB-1 (H16-YB-1), and the expression of YB-1 was verified by PCR ( Figure 1a , lanes 3-5), Northern blot hybridization (Figure 1c, top) , and immunoblotting (Figure 1c, bottom) . In H16-YB-1 cells, YB-1 protein was increased both in the nucleus and the cytoplasm by a factor B1.75 as compared to H16N2 cells. The SUM-149PT breast cancer cells used to construct the library overexpressed YB-1 mRNA and nuclear YB-1 protein as compared to H16N2 cells, but cytoplasmic YB-1 was similar to H16N2 cells. We compared the growth of H16N2 and H16-YB-1 cells in serum-free medium with and without EGF (Figure 1d ). In contrast to H16N2 cells, H16-YB-1 cells were able to proliferate in SFH medium. However, the growth rate of H16-YB-1 cells was further increased in SFIHE medium.
Repeat infections of H16N2 with the YB-1 cDNA also yielded EGF-independent colonies, and several clones from two independent experiments have been propagated for multiple passages in SFH medium. To determine if other cell lines could gain growth factor independence after YB-1 transduction, we introduced YB-1 cDNA into HMEC that have been immortalized with the gene for the telomerase reverse transcriptase (Elenbaas et al., 2001) . In this genetic context, YB-1 also resulted in the emergence of EGF-independent cells (data not shown). Therefore, this phenomenon is not limited to a single cell line.
EGFR is overexpressed and constitutively phosphorylated in YB-1-transduced cells
Since YB-1 has previously been cloned for its ability to bind to an EGFR enhancer region (Sakura et al., 1988) , it might regulate EGFR expression directly. To determine whether EGFR mRNA levels were elevated in YB-1-overexpressing cells, we performed Northern blot hybridizations in H16N2 parental cells and in six YB-1-transduced H16N2 cell clones obtained in four separate infections. Five out of six YB-1-overexpressing clones expressed moderately elevated mRNA levels as compared to H16N2 cells (Figure 2 and data not shown). We developed an H16N2 variant cell line where YB-1 is inducible with tetracycline (HTR-YB#5). Upon induction with 1 mg/ml tetracycline for 24 h, EGFR mRNA levels increased B2.8-fold (Figure 2) . Thus, YB-1 may regulate EGFR at the transcriptional level in these cells.
To determine whether EGFR protein was elevated, we performed immunofluorescence and immunoblotting. These experiments showed that membrane EGFR levels were increased in H16-YB-1 cells compared to parental H16N2 cells (Figures 3 and 4b) . This was also the case for 4-4#1 and 3-3PC clones (data not shown). In contrast, membrane ErbB-2 levels were unchanged in H16-YB-1 cells compared to controls (Figure 3) . EGF treatment at 10 ng/ml for 16 h reduced both EGFR and ErbB-2 membrane staining in parental H16N2 cells as well as in H16-YB-1 (Figure 3 ), presumably by EGFstimulated endocytosis of both receptors.
The amount of active, tyrosine-phosphorylated EGFR was markedly increased in H16-YB-1 cells grown in the absence of EGF compared to H16N2 cells grown in the same medium (Figure 4 ). Immunofluorescence staining with an antibody specific to phosphorylated EGFR shows that, in the absence of EGF, activated EGFR is mostly membrane-associated in H16-YB-1 cells, and barely detectable in H16N2 cells (Figure 4a ). Upon incubation with 10 ng/ml EGF for 5 min, phosphorylated EGFR staining in H16-YB-1 cells shows a redistribution on the plasma membrane consistent with the early steps of internalization, and membrane as well as vesicular staining can be seen in H16N2 cells. Anti-phosphotyrosine immunoblotting of membrane extracts and EGFR immunoprecipitates of whole-cell extracts confirmed the constitutive phosphorylation of EGFR in H16-YB-1 cells (Figure 4b ). The extent of EGFR phosphorylation at one of the major autophosphorylation sites, Tyr 1068, was determined in the absence and presence of EGF by immunoblotting with a phospho-specific antibody (Figure 4c ). In the absence of EGF, the specific activity of EGFR (ratio of phosphorylated to total EGFR) was B4.6-fold higher in H16-YB-1 cells than in H16N2 cells. EGF treatment for 24 h drastically reduced the total EGFR levels in both cell lines, but increased the specific activity by a factor B15 in H16N2 cells and by a factor B2 in H16-YB-1 cells.
Autocrine EGFR ligands are not driving EGF independence in YB-1 transduced cells
To determine if secreted growth factor ligands were responsible for EGFR activation and proliferation in H16-YB-1 cells, we used the clone 225 (Ab-3) (Sato et al., 1983) . Ab-3 did not reduce the proliferation of H16-YB-1 cells in SFH medium, or that of EGFRnegative SUM-52 breast cancer cells (Figure 5a ). However, Ab-3 was able to block the proliferation of M5#1 cells, a separately derived EGF-independent cell line that overexpresses EGFR and secretes EGF-family growth factors. Clone EGFR.1 (Ab-5), an antibody which binds to the extracellular domain of EGFR without interfering with ligand binding (Waterfield et al., 1982) , had a moderate stimulatory effect in this assay towards H16-YB-1. Ab-5 binding may induce a conformation change in EGFR or stabilize EGFR dimers by crosslinking, thus leading to partial activation and growth stimulation in the absence of natural ligand.
We next assayed conditioned media from H16-YB-1 cells for EGF-like mitogenic activity. After repeated attempts, no significant activity was detected in conditioned medium from H16-YB-1 cells (Figure 5b ). In contrast, conditioned medium from M5#1 cells stimulated growth of H16N2 in EGF-free medium, and stimulation was sensitive to anti-EGFR blocking antibody ( Figure 5b ). Moreover, the synthesis of EGFR ligands was reduced in YB-1-transduced cells relative to parental H16N2 cells as measured by real-time RT-PCR ( Figure 5c ). Amphiregulin, epiregulin, and HB-EGF mRNA levels were significantly reduced in H16-YB-1 and two independent YB-1 clones obtained in separate experiments (clone 3-3PC, polyclonal, and clonally derived 4-1#1). EGF, betacellulin, and TGF-a were not significantly different from H16N2 cells. These results indicate that YB-1 does not induce EGF-like growth factors.
ErbB kinase activity is required for EGF independence in YB-1-transduced cells
To investigate the dependence of YB-1-transduced cells on EGFR-activated signaling for proliferation in SFH medium, we performed growth assays in the presence of 0.1 or 1 mM CI-1033, a kinase inhibitor specific for the ErbB family (Fry et al., 1998; Smaill et al., 2000) . This inhibitor was slightly less potent in reducing the proliferation of H16-YB-1 cells compared to amphiregulin-overexpressing H16-AR cells ( Figure 6 ). Moreover, EGFR autophosphorylation was still detectable after treating H16-YB-1 cells for 24 h with 1 mM CI-1033 ( Figure 6b ). However, H16-YB-1 cell growth could be blocked completely with daily treatment with 1 mM . H16N2 cells were grown in SFIHE, then switched to SFH medium overnight and YB-1 clones were grown continuously in SFH medium. EGFR levels were moderately increased in H16-YB-1 and 4-1#1 as compared to parental H16N2 cells (1.65-and 2.0-fold, respectively). Lanes 4-5: Northern blot hybridization in H16N2 cells containing a tetracycline-inducible YB-1 cDNA. HTR-YB#5 cells were grown in SFIHE and incubated for 24 h with vehicle control (lane 4) or 1 mg/ml tetracycline (lane 5) for 24 h. EGFR mRNA levels were increased B2.8-fold upon YB-1 induction Figure 3 YB-1 overexpression increases EGFR but not ErbB-2 protein levels. Immunofluorescent staining for surface EGFR and ErbB-2. Cells were grown overnight in the absence or presence of 10 ng/ml EGF as indicated. Cells were incubated at 41C with primary antibody to EGFR or ErbB-2, then to rhodamineconjugated anti-mouse IgG secondary antibody. Control cells were incubated without primary antibody. Bar, 50 mm. All pictures were taken with the same exposure time and settings YB-1 confers EGF independence IM Berquin et al CI-1033, and EGFR phosphorylation was undetectable after treating cells for three consecutive days at the same concentration. This suggests that YB-1 induces EGF independence mostly through the EGFR family signaling pathway, and not by activating other mitogenic Phospho-Tyr1068-EGFR and total EGFR in H16N2 and H16-YB-1 cells. Whole-cell extracts from H16N2 cells grown for 24 h in the absence or presence of EGF (lanes 1 and 2, respectively) and H16-YB-1 cells grown for 24 h in the absence or presence of EGF (lanes 3 and 4, respectively) were sequentially immunoblotted with antiphospho-Tyr1068-EGFR (top), anti-EGFR (middle), and antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH, bottom) as a loading control. Blots were scanned and density was determined to calculate the ratio of phospho-EGFR to total EGFR relative to lane 1, arbitrarily set at 1. Specific activity data shown are the average of two independent experiments with standard deviations in parentheses (Figure 3 ), but ErbB-3 and ErbB-4 were not detected (data not shown). Since YB-1 transduction increased EGFR but not ErbB-2 levels, EGFR activation most likely plays a major role in YB-1-mediated EGF independence.
Discussion
Unlike gliomas and other tumor types, breast tumors present relatively infrequent EGFR gene amplifications or mutations. However, EGFR positivity in breast cancer is an indicator of tumor aggressiveness, early relapse, and poor prognosis (Klijn et al., 1992; Fox and Harris, 1997; Salomon et al., 2000; Nicholson et al., 2001) . In addition, EGFR expression in breast cancer cells frequently accompanies hormone independence (Gee et al., 2003) , and EGFR-specific therapies may be of benefit for some breast cancer patients. Transgenic mice expressing the human EGFR in the mammary gland develop neoplasia (Brandt et al., 2000) . Therefore, EGFR may play a role in breast cancer pathogenesis. The acquisition of progressive growth factor independence in human and rat mammary epithelial cells correlates with increasing aggressiveness in vivo (Ethier, 1995) . We hypothesized that genetic alterations which result in EGFR overexpression or activation may confer EGF independence to breast cancer cells and increase their aggressiveness. To identify candidate genes that mediate growth factor autonomy, we expressed cDNAs from a breast cancer library into HMECs and selected cells that acquired EGF independence. Using this strategy, we have previously isolated a cDNA encoding the EGF family member amphiregulin, and we demonstrated that amphiregulin acts in an autocrine fashion through the EGFR in the donor breast cancer cell line (Berquin et al., 2001 ). The present report describes the isolation of another cDNA, encoding the transcriptional and translational regulator, YB-1. The fact that YB-1 can confer EGF independence raises the possibility that this gene product might contribute to the reduced growth requirement of cancer cells in vivo. This may explain in part the presence and prognostic significance of elevated YB-1 protein in breast cancer (Bargou et al., 1997; Sorlie et al., 2001; Janz et al., 2002; Rubinstein et al., 2002) . YB-1 can bind RNA as well as single-and doublestranded DNA, and regulates gene expression at the transcriptional and translational levels (reviewed in Matsumoto and Wolffe, 1998; Swamynathan et al., 1998; Kohno et al., 2003) . YB-1 may also be involved in DNA repair (Ohga et al., 1996; Marenstein et al., 2001; Gaudreault et al., 2004) . As a transcription factor, YB-1 binds the inverted CCAAT, or Y-box sequence found in the promoter regions of several genes controlling cell growth (Didier et al., 1988; Ladomery and Sommerville, 1995) . YB-1 also binds to promoter elements with CT strand asymmetry (Kolluri et al., 1992) . Both types of elements can be found in the EGFR gene. Noticeably, dbpB (YB-1) was cloned by its ability to bind an EGFR enhancer (Sakura et al., 1988) , which suggests that YB-1 may regulate EGFR expression directly. Our data showed that EGFR mRNA and protein levels were modestly increased in YB-1-overexpressing H16-YB-1 cells compared to parental H16N2 cells. This suggests that YB-1 might regulate EGFR at the transcriptional level. In addition, the amount of active, tyrosinephosphorylated EGFR was markedly increased in H16-YB-1 cells grown in the absence of EGF compared to H16N2 cells. When deprived of EGF overnight, H16N2 cells showed a transient increase in EGFR levels and phosphorylation (Figure 4b and c) , but upon prolonged starvation, the cells stopped proliferating (Figure 1d ). By contrast, H16-YB-1 cells have been growing continuously for many generations in SFH medium and maintained high phosphorylated EGFR levels.
A blocking antibody that prevents ligand binding to EGFR failed to reduce the proliferation of H16-YB-1 cells, suggesting that secreted ligands were not responsible for receptor activation. Consistently, no significant EGF-like conditioned medium activity was detected. However, EGFR can be activated intracellularly by ligands in vesicular compartments. Therefore, we measured the mRNA levels of six EGFR ligands by real-time RT-PCR. Our results show that the overall synthesis of these ligands was reduced in YB-1-transduced cells relative to parental H16N2 cells. This decrease in ligand synthesis may be a direct effect of YB-1 overexpression, perhaps transcriptional repression by YB-1 itself. On the other hand, the ligands may be reduced by a compensatory mechanism caused by EGFR accumulation. The genes for epiregulin, amphiregulin, and betacellulin are clustered together on chromosome 4q13-q21. The EREG and AREG genes, which were both strongly reduced in H16-YB-1 cells, are in the same orientation and within 100 kb of each other, and their expression may be coregulated. In contrast, the BTC gene, which was unchanged by YB-1 overexpression, is situated 400 kb away from EREG and in the opposite orientation. Of the six ligands tested, betacellulin was the most abundant in YB-1-transduced cells. However, the fact that its levels were similar to H16N2 cells suggests that this ligand is not the driving force behind EGF independence. In addition, immunofluorescent staining with antiphosphorylated EGFR suggested that the bulk of activity is membraneassociated, and not vesicular as would be expected if EGFR became activated by ligands in the secretory compartment. Interestingly, H16-YB-1 cell proliferation could still be blocked with an ErbB kinase inhibitor at concentrations shown to be specific for receptors of the EGFR family. However, complete inhibition of EGFR autophosphorylation and cell growth required more frequent inhibitor administration in H16-YB-1 cells, presumably due to the elevated rate of EGFR synthesis in these cells. Since CI-1033 binds irreversibly to its target, the inhibitor may become depleted and newly synthesized receptors may escape inhibition in cells expressing high levels of ErbB receptors. H16-YB-1 cells express EGFR and ErbB-2, but ErbB-3 and ErbB-4 were not detected (data not shown). Since ErbB-2 expression was unchanged upon YB-1 transduction, EGFR most likely plays a key role in EGF independence of H16-YB-1 cells. However, ErbB-2 may also participate in signaling by forming heterodimers with EGFR, as suggested by the disappearance of ErbB-2 labeling from the cell surface after EGF treatment.
Taken together, our results clearly demonstrate that overexpression of YB-1 in HMECs can induce an EGFindependent growth phenotype via activation of the EGFR pathway. Accordingly, the EGF-independent SUM-149PT cells, from which the library was derived, overexpress both YB-1 and constitutively activated EGFR, which is necessary for cell growth. What remains unclear at this point is the mechanism of EGFR activation in the YB-1-transduced HMECs. The current understanding of EGFR activation is that ligand binding induces a conformational change that exposes a dimerization loop in the extracellular domain, allowing dimerization and activation of two EGFR monomers only when each is occupied by ligand (Lemmon et al., 1997; Schlessinger, 2002) . By contrast, the dimerization loop of ErbB-2 is thought to be maintained in an open conformation, and ErbB-2 can dimerize in the absence of ligand binding. This difference in the mode of activation of the two receptors may explain why in breast cancer, the ErbB-2 gene is frequently amplified, whereas EGFR is not. There is, however, evidence suggesting that ligand-activated EGFR molecules can activate unoccupied EGFR: local stimulation of cells with EGF triggers a rapid lateral propagation of EGFR phosphorylation throughout the cell membrane (Verveer et al., 2000) . This effect requires high EGFR density on the cell surface (Sawano et al., 2002) . Therefore, in EGFR-overexpressing cells such as H16-YB-1 cells, global EGFR signaling could become activated in the presence of reduced ligand levels. The SUM-149PT cells express high levels of both YB-1 and amphiregulin and, thus, these two proteins likely interact in mediating the EGF-independence phenotype in these cells. However, HMECs transfected with YB-1 alone showed significant downregulation of amphiregulin mRNA, as well as most other EGFR ligands. Thus, it is possible that YB-1 alters cells in a way that allows them to respond to very low concentrations of ligand, or that H16-YB-1 cells are differentially responsive to betacellulin. On the other hand, EGFR has been shown to become activated in a ligand-independent fashion through substrate attachment and integrin activation (Moro et al., 1998) or through crosstalk with other cell surface receptors (Daub et al., 1996; Moghal and Sternberg, 1999; Saito et al., 2001; Wan et al., 2001) . Therefore, YB-1 overexpression could alter EGFR dynamics in a way that results in true ligand independence. Further work will be needed to distinguish between these possibilities.
In normal cells, growth factors are required to initiate and maintain the cell cycle transition from G1 to S. Cancer cells can become independent from growth factors for this checkpoint. Our studies and others have shown that immortal cells can acquire growth factor independence through acquisition of autocrine growth factors (Li et al., 1992; Shirakata et al., 2000; Berquin et al., 2001) or growth factor receptor overexpression (Woods Ignatoski et al., 1999; Worthylake et al., 1999; Nair et al., 2001) . In the present study, we found that YB-1 lead to overexpression and activation of EGFR and to EGF-independent proliferation in HMECs. Y-box proteins are expressed at high levels in proliferating tissues, and a role for YB-1 in activating growthassociated genes has been proposed (Grant and Deeley, 1993; Ladomery and Sommerville, 1995; Shibao et al., 1999) . Interestingly, YB-1 has been shown to relocalize from the cytoplasm to the nucleus at the G1/S phase transition (Jurchott et al., 2003) . Moreover, in a YB-1-overexpressing cell line, nuclear YB-1 accumulation correlated with increased cyclins A and B1, which may result in adhesion-independent cell proliferation. Disruption of one Chk-YB-1b allele in a chicken pre-B lymphocyte cell line resulted in G2/M cell cycle arrest (Swamynathan et al., 2002) . These findings suggest that YB-1 may promote both cell cycle G1/S and G2/M transitions by increasing the levels of several growth YB-1 confers EGF independence IM Berquin et al regulators. YB-1 may participate in other tumor phenotypes, such as multidrug resistance (Bargou et al., 1997) , genomic instability (Kajino et al., 2001) , and metastasis (Mertens et al., 1998) . Together with reduced growth requirements, these possible phenotypic consequences of YB-1 overexpression may contribute to breast cancer cell aggressiveness and poor patient prognosis. Therefore, YB-1 could be a valuable target for gene-specific therapy in breast cancer and other cancer types. Table 1 lists all cells used in this report. SUM-149PT cells were maintained in Ham's F-12 with 5% fetal bovine serum (FBS), 5 mg/ml insulin, 2 mg/ml hydrocortisone, 5 mg/ml gentamicin, and 2.5 mg/ml fungizone. The serum-free base medium for selecting growth factor-independent clones was SFH: Ham's F-12 with 1 mg/ml hydrocortisone, 1 mg/ml bovine serum albumin (BSA), 10 mM N-[2-hydroxyethyl]piperazine-N 0 -[2-ethanesulfonic acid], 5 mM ethanolamine, 5 mg/ml transferrin, 10 nM triiodothyronine, 50 nM sodium selenate, 5 mg/ml gentamicin, and 2.5 mg/ml fungizone. H16-YB-1 and H16-AR cells were maintained in SFH. Parental H16N2 cells (Band and Sager, 1989; Band et al., 1990) were maintained in SFH medium supplemented with 5 mg/ml insulin and 10 ng/ml EGF (SFIHE). H16N2 cells with tetracycline-inducible YB-1 expression (HTR-YB#5) were generated using the T-Rex system (Invitrogen, Carlsbad, CA, USA) and maintained in SFIHE medium with 2 mg/ml blasticidin and 50 mg/ml zeocin. EGFR-negative SUM-52 cells and EGF-independent MCF-10A clone M5#1 were maintained in SFH medium supplemented with 5 mg/ml insulin (SFIH). All cells were kept in a humidified incubator at 371C and 10% CO 2 .
Materials and methods
Cell culture
Expression cloning
This method was described earlier (Berquin et al., 2001) . Briefly, a cDNA expression library was constructed from SUM-149PT breast cancer cells in pBabeMN retroviral vector (Kinoshita et al., 1997) and transfected into FNX-Ampho producer cells. The resulting retroviral library was used to infect H16N2 recipient cells. At 24 h postinfection, cells were split 1 : 6 in SFH for selection. Colonies were isolated by ring cloning and propagated in the same media. cDNAs were recovered by RT-PCR using vector-specific primers, subcloned into pBabeMN retroviral vector, and sequenced. For functional analysis of candidate inserts, H16N2 cells were infected with retrovirus prepared from isolated cDNAs, then selected in SFH medium. Colonies were stained with Giemsa.
Northern blotting for EGFR and YB-1
Total cellular RNA was prepared with Trizol (Invitrogen). RNA (5 mg) was fractionated on 0.8% agarose formaldehyde gels and transferred to a positively charged Nylon membrane. A 1.5-kb YB-1 cDNA probe was labeled with digoxigenin, then Northern blot hybridization and detection were performed using the DIG-high prime DNA labeling/detection starter kit II (Roche Applied Science, Indianapolis, IN, USA). For EGFR, a fragment (nt 3560-3708) was labeled by PCR amplification in the presence of 70 mM DIG-11dUTP (Roche), then hybridization and detection were performed as above. Films were scanned to determine the relative expression of EGFR and YB-1 mRNA using Adobe Photoshop (Adobe Systems Inc., San Jose, CA, USA), and expression was normalized to 18S RNA signal.
Immunofluorescent staining for EGFR and ErbB-2
Staining was performed as described (Willingham and Pastan, 1985) . Briefly, for cell surface staining, live cells were incubated at 41C for 1 h with primary antibody to EGFR (Ab-5, Calbiochem, San Diego, CA, USA) or ErbB-2 (4D5, Genentech, Inc., San Francisco, CA, USA), then diluted to 1 mg/ml in PBS containing 1% BSA. Cells were washed with PBS, and then incubated at 41C for 30 min with rhodamineconjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Cells were washed again, and then fixed with 3.7% formaldehyde in PBS for 10 min. For intracellular staining with phosphorylated EGFR monoclonal antibody (Phospho-Tyr 1068, Cell Signaling Technology, Beverly, MA, USA), cells were first fixed with Permiflow (Invirion, Frankfort, MI, USA) for 10 min at room temperature, then washed and incubated with primary and secondary antibodies in PBS containing 1% BSA. Cells were mounted with 90% glycerol in PBS and examined using a Zeiss Axioplan 2 fluorescence microscope.
Immunoblotting and immunoprecipitations
Whole cell, membrane, cytoplasmic, or nuclear protein samples were prepared as described previously (Sartor et al., 1997; Woods Ignatoski et al., 1999) . Samples were separated by standard SDS-polyacrylamide gel electrophoresis and electroblotted onto Immobilon-P PVDF membranes (Millipore, Bedford, MA, USA). For YB-1 immunoblotting, nuclear 
Proliferation assays
For growth curve experiments, cells were seeded on day 0 in 24-well plates at 1.5 Â 10 4 cells/well in their respective media supplemented with 2% FBS. On day 1 and every 2-3 days thereafter, cells were fed with the indicated serum-free media. For the ErbB kinase inhibitor assay, starting on day 4, cells were treated three times per week with vehicle control (DMSO), 0.1 or 1 mM CI-1033 ErbB kinase inhibitor, or cells were treated daily with 1 mM CI-1033. Cells were counted in triplicate on the indicated days using a Coulter Counter (Beckman, Miami, FL, USA). Proliferation assays with blocking antibodies or conditioned media were performed using the CCK-8 kit (Dojindo Molecular Technologies, Gaithersburg, MD, USA). Cells were seeded in 96-well plates at 1 Â 10 3 cells/well on day 0 in their usual media supplemented with 2% FBS. Cells were treated in triplicate with 2 mg/ml anti-EGFR antibody (Ab-3, clone 225 or Ab-5, clone EGFR.1, Calbiochem) or control serum-free media (SFH for H16N2-YB-1, SFIH for M5#1 and SUM-52) on days 1, 3, and 6. On day 8, 10 ml CCK-8 reagent was added in each well, then plates were incubated at 371C for 2 h before measuring the absorbance at 450 nm using a microplate reader. Results are expressed as background-subtracted optical density units (OD), and are the average of two independent experiments. Previous calibration curves performed with known numbers of cells/well have shown good linearity of the assay. For conditioned media assays, H16N2 cells were plated as above and treated in triplicate on days 1, 3, and 6 with conditioned media mixed with an equal volume of fresh SFH medium. Conditioned media were harvested from subconfluent monolayers of H16N2, H16-YB-1, or M5#1 cells fed with EGF-free medium and incubated for 48 h at 371C. In some wells, 2 mg/ml Ab-3 anti-EGFR antibody was added to conditioned media. Cells were quantitated on day 8 as described above.
Real-time RT-PCR
Total RNA was isolated from subconfluent cell cultures using Trizol (Invitrogen). cDNA was reverse-transcribed from 2 mg of total RNA using the Omniscript kit (Qiagen, Valencia, CA, USA). Dilutions of a reference RT product were used to construct standard curves for each target gene, and run on the same plate with the samples for each assay. Real-time quantitative RT-PCR was performed on an iCycler (BioRad, Hercules, CA, USA) using the QuantiTect SYBR Green PCR Kit (Qiagen). Primers used were (forward, reverse): peptidyl prolyl isomerase B (PPIB) (gcccaaagtcaccgtcaa, tccgaagagac caaagatcac), amphiregulin (ggtggtgctgtcgctctt, gcttcccagag taggtgtcatt), betacellulin (ttccaccagaagtcctgaaac, ctttcc gctttgattgtgtg), EGF (ggagtcgagcagagatgtgag, ccattcttgagg tcttggtgtt), epiregulin (tggctttgaccgtgattctt, tctcatattcctt ctttggttctttac), heparin-binding EGF-like growth factor (HB-EGF, gctgtggtgctgtcatctgt, tcatgcccaacttcactttct), and TGF-a (tgcccagattcccacact, tacccagaatggcagacaca). Each primer pair spans at least one splice junction. PCR reactions contained 100 pM of primers and 10 ng of reverse transcribed total RNA in 25 ml. PCR was performed with an initial 10-min denaturation at 951C followed by 50 cycles of a two-step PCR (15 s at 951C, then 1 min at 601C). Data for each gene was normalized to the housekeeping control PPIB using the Q-Gene software application (Muller et al., 2002) , and presented as mean normalized mRNA expression from two independent experiments performed in triplicate.
